CASI Pharmaceuticals recently announced that the company expects its common stock to be quoted on the over-the-counter (OTC) market operated by OTC Markets Group.

This move marks a significant shift for the company’s stock trading platform. The OTC market, as a non-exchange trading platform, provides investors with more flexible trading channels. This adjustment by Kexin Yuanda aims to broaden stock liquidity and attract a wider range of investors. The company stated that it will continue to comply with relevant market regulatory requirements to ensure that shareholders’ interests are fully protected.